Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetes

Cytokine

Volumn 60, Issue 1, 2012, Pages 1-12

  Panee, Jun ^a  

^a UNIVERSITY OF HAWAII   (United States)

Author keywords

Diabetes; Diabetic complications; Inflammation; MCP 1; Obesity

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; BREVISCAPINE; CANDESARTAN; CAPSAICIN; CERIVASTATIN; CILOSTAZOL; CLOFIBRATE; DOXAZOSIN; ENALAPRIL; FENOFIBRATE; GLICLAZIDE; IRBESARTAN; LISINOPRIL; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLMESARTAN; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; SPIRONOLACTONE; TRIPTOLIDE; TROGLITAZONE; UNINDEXED DRUG; VALSARTAN;

ADIPOGENESIS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GENE; GENE EXPRESSION REGULATION; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULITIS; METABOLIC SYNDROME X; MONOCYTE CHEMOATTRACTANT PROTEIN 1GENE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEINURIA; REGULATORY MECHANISM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION;

ANIMALS; CARDIOVASCULAR DISEASES; CHEMOKINE CCL2; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY; HUMANS; OBESITY; SIGNAL TRANSDUCTION;

EID: 84865410857     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.06.018     Document Type: Review

References (225)

1. Matsushima K., Larsen C.G., DuBois G.C., Oppenheim J.J. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med 1989, 169:1485-1490.
2. Larsen C.G., Zachariae C.O., Oppenheim J.J., Matsushima K. Production of monocyte chemotactic and activating factor (MCAF) by human dermal fibroblasts in response to interleukin 1 or tumor necrosis factor. Biochem Biophys Res Commun 1989, 160:1403-1408.
3. Yoshimura T., Yuhki N., Moore S.K., Appella E., Lerman M.I., Leonard E.J. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett 1989, 244:487-493.
4. Yoshimura T., Robinson E.A., Tanaka S., Appella E., Kuratsu J., Leonard E.J. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med 1989, 169:1449-1459.
5. Yoshimura T., Robinson E.A., Tanaka S., Appella E., Leonard E. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 1989, 142:1956-1962.
6. Robinson E.A., Yoshimura T., Leonard E.J., Tanaka S., Griffin P.R., Shabanowitz J., et al. Complete amino acid sequence of a human monocyte chemoattractant, a putative mediator of cellular immune reactions. Proc Natl Acad Sci USA 1989, 86:1850-1854.
7. Furutani Y., Nomura H., Notake M., Oyamada Y., Fukui T., Yamada M., et al. Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem Biophys Res Commun 1989, 159:249-255.
8. Van Coillie E., Van Damme J., Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev 1999, 10:61-86.
9. Naruse K., Ueno M., Satoh T., Nomiyama H., Tei H., Takeda M., et al. A YAC contig of the human CC chemokine genes clustered on chromosome 17q11.2. Genomics 1996, 34:236-240.
10. Proost P., Struyf S., Couvreur M., Lenaerts J.P., Conings R., Menten P., et al. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2(6-76) as a natural chemokine inhibitor. J Immunol 1998, 160:4034-4041.
11. Charo I.F., Myers S.J., Herman A., Franci C., Connolly A.J., Coughlin S.R. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 1994, 91:2752-2756.
12. Wong L.M., Myers S.J., Tsou C.L., Gosling J., Arai H., Charo I.F. Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J Biol Chem 1997, 272:1038-1045.
13. Sica A., Wang J.M., Colotta F., Dejana E., Mantovani A., Oppenheim J.J., et al. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor. J Immunol 1990, 144:3034-3038.
14. Cushing S.D., Berliner J.A., Valente A.J., Territo M.C., Navab M., Parhami F., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990, 87:5134-5138.
15. Standiford T.J., Kunkel S.L., Phan S.H., Rollins B.J., Strieter R.M. Alveolar macrophage-derived cytokines induce monocyte chemoattractant protein-1 expression from human pulmonary type II-like epithelial cells. J Biol Chem 1991, 266:9912-9918.
16. Brown Z., Strieter R.M., Neild G.H., Thompson R.C., Kunkel S.L., Westwick J. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int 1992, 42:95-101.
17. Barna B.P., Pettay J., Barnett G.H., Zhou P., Iwasaki K., Estes M.L. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor(TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol 1994, 50:101-107.
18. Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003, 100:7265-7270.
19. Huber J., Kiefer F.W., Zeyda M., Ludvik B., Silberhumer G.R., Prager G., et al. CC chemokine and CC chemokine receptor profiles in visceral and subcutaneous adipose tissue are altered in human obesity. J Clin Endocrinol Metab 2008, 93:3215-3221.
20. Harman-Boehm I., Blüher M., Redel H., Sion-Vardy N., Ovadia S., Avinoach E., et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab 2007, 92:2240-2247.
21. Shyy Y.J., Li Y.S., Kolattukudy P.E. Structure of human monocyte chemotactic protein gene and its regulation by TPA. Biochem Biophys Res Commun 1990, 169:346-351.
22. Ueda A., Okuda K., Ohno S., Shirai A., Igarashi T., Matsunaga K., et al. NF-kB and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol 1994, 153:2052.
23. Ueda A., Ishigatsubo Y., Okubo T., Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. J Biol Chem 1997, 272:31092.
24. Timmers H.T., Pronk G.J., Bos J.L., van der Eb A.J. Analysis of the rat JE gene promoter identifies an AP-1 binding site essential for basal expression but not for TPA induction. Nucleic Acids Res 1990, 18:23-34.
25. Hanazawa S., Takeshita A., Amano S., Semba T., Nirazuka T., Katoh H., et al. Tumor necrosis factor-alpha induces expression of monocyte chemoattractant JE via fos and jun genes in clonal osteoblastic MC3T3-E1 cells. J Biol Chem 1993, 268:9526-9532.
26. Ping D., Jones P.L., Boss J.M. TNF regulates the in vivo occupancy of both distal and proximal regulatory regions of the murine monocyte chemoattractant protein-1 (MCP-1/JE) gene. Immunity 1996, 4:455.
27. Ping D., Boekhoudt G.H., Rogers E.M., Boss J.M. Nuclear factor-kappa B p65 mediates the assembly and activation of the TNF-responsive element of the murine monocyte chemoattractant-1 gene. J Immunol 1999, 162:727-734.
28. Piemonti L., Leone B.E., Nano R., Saccani A., Monti P., Maffi P., et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002, 51:55-65.
29. Chen M.C., Proost P., Gysemans C., Mathieu C., Eizirik D.L. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 2001, 44:325-332.
30. Kutlu B., Darville M.I., Cardozo A.K., Eizirik D.L. Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta-cells. Diabetes 2003, 52:348-355.
31. Kharroubi I., Lee C.H., Hekerman P., Darville M.I., Evans R.M., Eizirik D.L., et al. BCL-6: a possible missing link for anti-inflammatory PPAR-delta signalling in pancreatic beta cells. Diabetologia 2006, 49:2350-2358.
32. Ortis F., Cardozo A.K., Crispim D., Störling J., Mandrup-Poulsen T., Eizirik D.L. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-kappaB activation. Mol Endocrinol 2006, 20:1867-1879.
33. Chipitsyna G., Gong Q., Gray C.F., Haroon Y., Kamer E., Arafat H.A. Induction of monocyte chemoattractant protein-1 expression by angiotensin II in the pancreatic islets and beta-cells. Endocrinology 2007, 148:2198-2208.
34. Mojsilovic-Petrovic J., Callaghan D., Cui H., Dean C., Stanimirovic D.B., Zhang W. Hypoxia-inducible factor-1 (HIF-1) is involved in the regulation of hypoxia-stimulated expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) and MCP-5 (Ccl12) in astrocytes. J Neuroinflammation 2007, 4:12.
35. Stowe A.M., Wacker B.K., Cravens P.D., Perfater J.L., Li M.K., Hu R., et al. CCL2 upregulation triggers hypoxic preconditioning-induced protection from stroke. J Neuroinflammation 2012, 9:33.
36. Lam S.Y., Liu Y., Ng K.M., Lau C.F., Liong E.C., Tipoe G.L., et al. Chronic intermittent hypoxia induces local inflammation of the rat carotid body via functional upregulation of proinflammatory cytokine pathways. Histochem Cell Biol 2012, 137:303-317.
37. Yu J., Shi L., Wang H., Bilan P.J., Yao Z., Samaan M.C., et al. Conditioned medium from hypoxia-treated adipocytes renders muscle cells insulin resistant. Eur J Cell Biol 2011, 90:1000-1015.
38. Famulla S., Horrighs A., Cramer A., Sell H., Eckel J. Hypoxia reduces the response of human adipocytes towards TNFα resulting in reduced NF-κB signaling and MCP-1 secretion. Int J Obes (Lond) 2011, [Epub ahead of print].
39. Dhawan L., Liu B., Blaxall B.C., Taubman M.B. A novel role for the glucocorticoid receptor in the regulation of monocyte chemoattractant protein-1 mRNA stability. J Biol Chem 2007, 282:10146-10152.
40. Catalán V., Gómez-Ambrosi J., Ramirez B., Rotellar F., Pastor C., Silva C., et al. Proinflammatory cytokines in obesity: impact of type 2 diabetes mellitus and gastric bypass. Obes Surg 2007, 17:1464-1474.
41. Breslin W.L., Johnston C.A., Strohacker K., Carpenter K.C., Davidson T.R., Moreno J.P., et al. Obese Mexican American children have elevated MCP-1, TNF-α, monocyte concentration, and dyslipidemia. Pediatrics 2012, [Epub ahead of print].
42. Bose T., Alvarenga J.C., Tejero M.E., Voruganti V.S., Proffitt J.M., Freeland-Graves J.H., et al. Association of monocyte chemoattractant protein-1 with adipocyte number, insulin resistance and liver function markers. J Med Primatol 2009, 38:418-424.
43. Lee Y.H., Lee S.H., Jung E.S., Kim J.S., Shim C.Y., Ko Y.G., et al. Visceral adiposity and the severity of coronary artery disease in middle-aged subjects with normal waist circumference and its relation with lipocalin-2 and MCP-1. Atherosclerosis 2010, 213:592-597.
44. Cox C.L., Stanhope K.L., Schwarz J.M., Graham J.L., Hatcher B., Griffen S.C., et al. Circulating concentrations of monocyte chemoattractant protein-1, plasminogen activator inhibitor-1, and soluble leukocyte adhesion molecule-1 in overweight/obese men and women consuming fructose- or glucose-sweetened beverages for 10 weeks. J Clin Endocrinol Metab 2011, 96:E2034-E2038.
45. Kelly K.R., Haus J.M., Solomon T.P., Patrick-Melin A.J., Cook M., Rocco M., et al. A low-glycemic index diet and exercise intervention reduces TNF(alpha) in isolated mononuclear cells of older, obese adults. J Nutr 2011, 141:1089-1094.
46. Sukumar D., Partridge N.C., Wang X., Shapses S.A. The high serum monocyte chemoattractant protein-1 in obesity is influenced by high parathyroid hormone and not adiposity. J Clin Endocrinol Metab 2011, 96:1852-1858.
47. Lorente-Cebrián S., Eriksson A., Dunlop T., Mejhert N., Dahlman I., Aström G., et al. Differential effects of 1α,25-dihydroxycholecalciferol on MCP-1 and adiponectin production in human white adipocytes. Eur J Nutr 2012, 51:335-342.
48. Higa J.K., Liu W., Berry M.J., Panee J. Supplement of bamboo extract lowers serum monocyte chemoattractant protein-1 concentration in mice fed a high fat diet. Brit J Nutr 2011, 106:1810-1813.
49. Hsieh P.S., Lu K.C., Chiang C.F., Chen C.H. Suppressive effect of COX2 inhibitor on the progression of adipose inflammation in high-fat-induced obese rats. Eur J Clin Invest 2010, 40:164-171.
50. Tateya S., Tamori Y., Kawaguchi T., Kanda H., Kasuga M. An increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. Endocrinology 2010, 151:971-979.
51. Younce C.W., Azfer A., Kolattukudy P.E. MCP-1 (monocyte chemotactic protein-1)-induced protein, a recently identified zinc finger protein, induces adipogenesis in 3T3-L1 pre-adipocytes without peroxisome proliferator-activated receptor gamma. J Biol Chem 2009, 284:27620-27628.
52. Weisberg S.P., Hunter D., Huber R., Lemieux J., Slaymaker S., Vaddi K., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006, 116:115-124.
53. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
54. Abe D., Saito T., Kubo Y., Nakamura Y., Sekiya K. A fraction of unripe kiwi fruit extract regulates adipocyte differentiation and function in 3T3-L1 cells. Biofactors 2010, (January 19). [Epub ahead of print].
55. Higa J.K., Panee J. Bamboo extract reduces interleukin 6 (IL-6) overproduction under lipotoxic conditions through inhibiting the activation of NFkappaB and AP-1 pathways. Cytokine 2011, 55:18-23.
56. Sugimoto M., Arai H., Tamura Y., Murayama T., Khaengkhan P., Nishio T., et al. Mulberry leaf ameliorates the expression profile of adipocytokines by inhibiting oxidative stress in white adipose tissue in db/db mice. Atherosclerosis 2009, 204:388-394.
57. Kang M.S., Hirai S., Goto T., Kuroyanagi K., Kim Y.I., Ohyama K., et al. Dehydroabietic acid, a diterpene, improves diabetes and hyperlipidemia in obese diabetic KK-Ay mice. Biofactors 2009, 35:442-448.
58. Kang M.S., Hirai S., Goto T., Kuroyanagi K., Lee J.Y., Uemura T., et al. Dehydroabietic acid, a phytochemical, acts as ligand for PPARs in macrophages and adipocytes to regulate inflammation. Biochem Biophys Res Commun 2008, 369:333-338.
59. Kang J.H., Tsuyoshi G., Han I.S., Kawada T., Kim Y.M., Yu R. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet. Obesity 2009, (October 1).
60. Kang J.H., Kim C.S., Han I.S., Kawada T., Yu R. Capsaicin, a spicy component of hot peppers, modulates adipokine gene expression and protein release from obese-mouse adipose tissues and isolated adipocytes, and suppresses the inflammatory responses of adipose tissue macrophages. FEBS Lett 2007, 581:4389-4396.
61. Jain S.K., Rains J., Croad J., Larson B., Jones K. Curcumin supplementation lowers TNF-alpha, IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF-alpha, IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. Antioxid Redox Signal 2009, 11:241-249.
62. Woo H.M., Kang J.H., Kawada T., Yoo H., Sung M.K., Yu R. Active spice-derived components can inhibit inflammatory responses of adipose tissue in obesity by suppressing inflammatory actions of macrophages and release of monocyte chemoattractant protein-1 from adipocytes. Life Sci 2007, 80:926-931.
63. Chacón M.R., Ceperuelo-Mallafré V., Maymó-Masip E., Mateo-Sanz J.M., Arola L., Guitiérrez C., et al. Grape-seed procyanidins modulate inflammation on human differentiated adipocytes in vitro. Cytokine 2009, 47:137-142.
64. Jeong H.W., Hsu K.C., Lee J.W., Ham M., Huh J.Y., Shin H.J., et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab 2009, 296:E955-E964.
65. Zhu J., Yong W., Wu X., Yu Y., Lv J., Liu C., et al. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun 2008, 369:471-477.
66. Nakamura K., Yamagishi S., Matsui T., Yoshida T., Imaizumi T., Makino T., et al. Acarbose, an alpha-glucosidase inhibitor, decreases aortic gene expression and serum levels of monocyte chemoattractant protein-1 in fructose-fed rats. J Int Med Res 2006, 34:525-530.
67. Tamura Y., Sugimoto M., Murayama T., Ueda Y., Kanamori H., Ono K., et al. Inhibition of CCR2 ameliorates insulin resistance and hepatic steatosis in db/db mice. Arterioscler Thromb Vasc Biol 2008, 28:2195-2201.
68. Jain S.K., Rains J.L., Croad J.L. High glucose and ketosis (acetoacetate) increases, and chromium niacinate decreases, IL-6, IL-8, and MCP-1 secretion and oxidative stress in U937 monocytes. Antioxid Redox Signal 2007, 9:1581-1590.
69. Jain S.K., Velusamy T., Croad J.L., Rains J.L., Bull R. L-cysteine supplementation lowers blood glucose, glycated hemoglobin, CRP, MCP-1, and oxidative stress and inhibits NF-kappaB activation in the livers of Zucker diabetic rats. Free Radic Biol Med 2009, 46:1633-1638.
70. Ghanim H., Garg R., Aljada A., Mohanty P., Kumbkarni Y., Assian E., et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001, 86:1306-1312.
71. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004, 89:2728-2735.
72. Kintscher U., Goetze S., Wakino S., Kim S., Nagpal S., Chandraratna R.A., et al. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes. Eur J Pharmacol 2000, 401:259-270.
73. Takebayashi K., Matsumoto S., Wakabayashi S., Inukai Y., Matsutomo R., Aso Y., et al. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism 2005, 54:1225-1229.
74. Sonoki K., Iwase M., Iino K., Ichikawa K., Yoshinari M., Ohdo S., et al. Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells. Eur J Pharmacol 2003, 475:139-147.
75. Wang T., Villegas S., Huang Y., White S.K., Ahlem C., Lu M., et al. Amelioration of glucose intolerance by the synthetic androstene HE3286: link to inflammatory pathways. J Pharmacol Exp Ther 2010, (January 12). [Epub ahead of print].
76. Tateya S., Tamori Y., Kawaguchi T., Kanda H., Kasuga M. An Increase in the circulating concentration of monocyte chemoattractant protein-1 elicits systemic insulin resistance irrespective of adipose tissue inflammation in mice. Endocrinology 2010, (January 7). [Epub ahead of print].
77. Lee M.H., Song H.K., Ko G.J., Kang Y.S., Han S.Y., Han K.H., et al. Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Kidney Int 2008, 74:890-900.
78. Cancello R., Henegar C., Viguerie N., Taleb S., Poitou C., Rouault C., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54:2277-2286.
79. Trøseid M., Lappegård K.T., Claudi T., Damås J.K., Mørkrid L., Brendberg R., et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J 2004, 25:349-355.
80. Bláha V., Andrýs C., Smahelová A., Knízek J., Hyspler R., Solichová D., et al. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover. Pharmacol Res 2006, 54:421-428.
81. Piemonti L., Calori G., Lattuada G., Mercalli A., Ragogna F., Garancini M.P., et al. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 2009, 32:2105-2110.
82. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000, 121:437-443.
83. Zietz B., Büchler C., Herfarth H., Müller-Ladner U., Spiegel D., Schölmerich J., et al. Caucasian patients with type 2 diabetes mellitus have elevated levels of monocyte chemoattractant protein-1 that are not influenced by the -2518 A→G promoter polymorphism. Diabetes Obes Metab 2005, 7:570-578.
84. Simeoni E., Hoffmann M.M., Winkelmann B.R., Ruiz J., Fleury S., Boehm B.O., et al. Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus. Diabetologia 2004, 47:1574-1580.
85. Rovin B.H., Lu L., Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Bioph Res Comm 1999, 259:344-348.
86. Karadeniz M., Erdogan M., Cetinkalp S., Berdeli A., Eroglu Z., Ozgen A.G. Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy. Endocrine 2010, 37:513-517.
87. Jing Y., Zhu D., Bi Y., Yang D., Hu Y., Shen S. Monocyte chemoattractant protein 1-2518 A/G polymorphism and susceptibility to type 2 diabetes in a Chinese population. Clin Chim Acta 2011, 412:466-469.
88. Kouyama K., Miyake K., Zenibayashi M., Hirota Y., Teranishi T., Tamori Y., et al. Association of serum MCP-1 concentration and MCP-1 polymorphism with insulin resistance in Japanese individuals with obese type 2 diabetes. Kobe J Med Sci 2008, 53:345-354.
89. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T.A., Imamura K., Ishibashi F., et al. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2010, 89:e9-e12.
90. Yuasa S., Maruyama T., Yamamoto Y., Hirose H., Kawai T., Matsunaga-Irie S., et al. MCP-1 gene A-2518G polymorphism and carotid artery atherosclerosis in patients with type 2 diabetes. Diabetes Res Clin Pract 2009, 86:193-198.
91. Ahluwalia T.S., Khullar M., Ahuja M., Kohli H.S., Bhansali A., Mohan V., et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. PLoS One 2009, 4:e5168.
92. Moon J.Y., Jeong L., Lee S., Jeong K., Lee T., Ihm C.G., et al. Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus. J Korean Med Sci 2007, 22:810-814.
93. Joo K.W., Hwang Y.H., Kim J.H., Oh K.H., Kim H., Shin H.D., et al. MCP-1 and RANTES polymorphisms in Korean diabetic end-stage renal disease. J Korean Med Sci 2007, 22:611-615.
94. Deo R., Khera A., McGuire D.K., Murphy S.A., Meo Neto Jde P., Morrow D.A., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 2004, 44:1812-1818.
95. de Lemos J.A., Morrow D.A., Sabatine M.S., Murphy S.A., Gibson C.M., Antman E.M., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 2003, 107:690-695.
96. Mazurek T., Zhang L., Zalewski A., Mannion J.D., Diehl J.T., Arafat H., et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation 2003, 108:2460-2466.
97. Arakelyan A., Petrkova J., Hermanova Z., Boyajyan A., Lukl J., Petrek M. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm 2005, 2005:175-179.
98. Tretjakovs P., Jurka A., Bormane I., Mackevics V., Mikelsone I., Balode L., et al. Relation of inflammatory chemokines to insulin resistance and hypoadiponectinemia in coronary artery disease patients. Eur J Intern Med 2009, 20:712-717.
99. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complicat 2006, 20:98-104.
100. de Lemos J.A., Morrow D.A., Blazing M.A., Jarolim P., Wiviott S.D., Sabatine M.S., et al. J Am Coll Cardiol 2007, 50:2117-2124.
101. Hohensinner P.J., Rychli K., Zorn G., Hülsmann M., Berger R., Mörtl D., et al. Macrophage-modulating cytokines predict adverse outcome in heart failure. Thromb Haemost 2010, 103:435-441.
102. Azfer A., Niu J., Rogers L.M., Adamski F.M., Kolattukudy P.E. Activation of endoplasmic reticulum stress response during the development of ischemic heart disease. Am J Physiol Heart Circ Physiol 2006, 291:H1411-H1420.
103. Zhou L., Azfer A., Niu J., Graham S., Choudhury M., Adamski F.M., et al. Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res 2006, 98:1177-1185.
104. Haubner F., Lehle K., Münzel D., Schmid C., Birnbaum D.E., Preuner J.G. Hyperglycemia increases the levels of vascular cellular adhesion molecule-1 and monocyte-chemoattractant-protein-1 in the diabetic endothelial cell. Biochem Biophys Res Commun 2007, 360:560-565.
105. Dragomir E., Manduteanu I., Calin M., Gan A.M., Stan D., Koenen R.R., et al. High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb Haemost 2008, 100:1155-1165.
106. Takaishi H., Taniguchi T., Takahashi A., Ishikawa Y., Yokoyama M. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochem Biophys Res Commun 2003, 305:122-128.
107. Luo P., Tan Z.H., Zhang Z.F., Zhang H., Liu X.F., Mo Z.J. Scutellarin isolated from Erigeron multiradiatus inhibits high glucose-mediated vascular inflammation. Yakugaku Zasshi 2008, 128:1293-1299.
108. Shanmugam N., Reddy M.A., Guha M., Natarajan R. High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003, 52:1256-1264.
109. Younce C.W., Wang K., Kolattukudy P.E. Hyperglycaemia-induced cardiomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovasc Res 2010, 87:665-674.
110. Shi A.H., Yoshinari M., Wakisaka M., Iwase M., Fujishima M. Lysophosphatidylcholine molecular species in low density lipoprotein of type 2 diabetes. Horm Metab Res 1999, 31:283-286.
111. Takahara N., Kashiwagi A., Nishio Y., Harada N., Kojima H., Maegawa H., et al. Oxidized lipoproteins found in patients with NIDDM stimulate radical-induced monocyte chemoattractant protein-1 mRNA expression in cultured human endothelial cells. Diabetologia 1997, (40):662-670.
112. Sánchez-Quesada J.L., Benítez S., Pérez A., Wagner A.M., Rigla M., Carreras G., et al. The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. Diabetologia 2005, 48:2162-2169.
113. Benítez S., Pérez A., Sánchez-Quesada J.L., Wagner A.M., Rigla M., Arcelus R., et al. Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control. Diabetes Metab Res Rev 2007, 23:26-34.
114. Sonoki K., Yoshinari M., Iwase M., Iino K., Ichikawa K., Ohdo S., et al. Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 2002, 51:1135-1142.
115. Sonoki K., Iwase M., Iino K., Ichikawa K., Ohdo S., Higuchi S., et al. Atherogenic role of lysophosphatidylcholine in low-density lipoprotein modified by phospholipase A2 and in diabetic patients: protection by nitric oxide donor. Metabolism 2003, 52:308-314.
116. Sima A.V., Botez G.M., Stancu C.S., Manea A., Raicu M., Simionescu M. Effect of irreversibly glycated LDL in human vascular smooth muscle cells: lipid loading, oxidative and inflammatory stress. J Cell Mol Med 2009, (October 10). [Epub ahead of print].
117. Toma L., Stancu C.S., Botez G.M., Sima A.V., Simionescu M. Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose. Biochem Biophys Res Commun 2009, 390:877-882.
118. Isoda K., Folco E., Marwali M.R., Ohsuzu F., Libby P. Glycated LDL increases monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated chemotaxis. Atherosclerosis 2008, 198:307-312.
119. Wen Y., Gu J., Chakrabarti S.K., Aylor K., Marshall J., Takahashi Y., et al. The role of 12/15-lipoxygenase in the expression of interleukin-6 and tumor necrosis factor-alpha in macrophages. Endocrinology 2007, 148:1313-1322.
120. Dwarakanath R.S., Sahar S., Reddy M.A., Castanotto D., Rossi J.J., Natarajan R. Regulation of monocyte chemoattractant protein-1 by the oxidized lipid, 13-hydroperoxyoctadecadienoic acid, in vascular smooth muscle cells via nuclear factor-kappa B (NF-kappa B). J Mol Cell Cardiol 2004, 36:585-595.
121. Li S.L., Dwarakanath R.S., Cai Q., Lanting L., Natarajan R. Effects of silencing leukocyte-type 12/15-lipoxygenase using short interfering RNAs. J Lipid Res 2005, 46:220-229.
122. Ohta M.Y., Nagai Y., Takamura T., Nohara E., Kobayashi K. Inhibitory effect of troglitazone on TNF-alpha-induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells. Diabetes Res Clin Pract 2000, 48:171-176.
123. Tikellis C., Jandeleit-Dahm K.A., Sheehy K., Murphy A., Chin-Dusting J., Kling D., et al. Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules. Atherosclerosis 2008, 199:55-64.
124. Pfützner A., Marx N., Lübben G., Langenfeld M., Walcher D., Konrad T., et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005, 45:1925-1931.
125. Ishibashi M., Egashira K., Hiasa K., Inoue S., Ni W., Zhao Q., et al. Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 2002, 40:687-693.
126. Dragomir E., Tircol M., Manduteanu I., Voinea M., Simionescu M. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 2006, 44:440-449.
127. Lin Y., Ye S., Chen Y., Li X., Yang G.W., Fan A., et al. The effect of simvastatin on the serum monocyte chemoattractant protein-1 and intracellular adhesion molecule-1 levels in diabetic rats. J Diabetes Complicat 2009, 23:214-218.
128. Blanco-Colio L.M., Martín-Ventura J.L., de Teresa E., Farsang C., Gaw A., Gensini G., et al. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on inflammatory markers study: a substudy of achieve cholesterol targets fast with atorvastatin stratified titration. Am Heart J 2007, 153:881-888.
129. Yu Y., Ohmori K., Chen Y., Sato C., Kiyomoto H., Shinomiya K., et al. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model. J Am Coll Cardiol 2004, 44:904-913.
130. Renier G., Mamputu J.C., Serri O. Benefits of gliclazide in the atherosclerotic process: decrease in monocyte adhesion to endothelial cells. Metabolism 2003, 52:13-18.
131. Mamputu J.C., Renier G. Gliclazide decreases vascular smooth muscle cell dysfunction induced by cell-mediated oxidized low-density lipoprotein. Metabolism 2001, 50:688-695.
132. Candido R., Allen T.J., Lassila M., Cao Z., Thallas V., Cooper M.E., et al. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 2004, 109:1536-1542.
133. Kintscher U., Kon D., Wakino S., Goetze S., Graf K., Fleck E., et al. Doxazosin inhibits monocyte chemotactic protein 1-directed migration of human monocytes. J Cardiovasc Pharmacol 2001, 37:532-539.
134. Murao K., Yu X., Cao W.M., Imachi H., Chen K., Muraoka T., et al. d-Psicose inhibits the expression of MCP-1 induced by high-glucose stimulation in HUVECs. Life Sci 2007, 81:592-599.
135. Lee Y.J., Kang D.G., Kim J.S., Lee H.S. Buddleja officinalis inhibits high glucose-induced matrix metalloproteinase activity in human umbilical vein endothelial cells. Phytother Res 2008, 22:1655-1659.
136. Zhang H., Chen S., Deng X., Yang X., Huang X. The effects of Danggui-Buxue-Tang on blood lipid and expression of genes related to foam cell formation in the early stage of atherosclerosis in diabetic GK rats. Diabetes Res Clin Pract 2007, 77:479-481.
137. Zhang H.M., Chen S.W., Xie C.G., Xie Y.Q., Deng X.F. Mechanism of Shenqi compound recipe anti-earlier diabetic artherosclerosis in GK rats. Zhongguo Zhong Yao Za Zhi 2006, 31:1272-1276.
138. Lameire N. Diabetes and diabetic nephropathy - a worldwide problem. Acta Diabetol 2004, 41:S3-S5.
139. Fioretto P., Steffes M.W., Brown D.M., Mauer S.M. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis 1992, 20:549-558.
140. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Rollins B.J., Tesch G.H. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
141. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
142. Morii T., Fujita H., Narita T., Shimotomai T., Fujishima H., Yoshioka N., et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complicat 2003, 17:11-15.
143. Chow F., Ozols E., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 2004, 65:116-128.
144. Mezzano S., Aros C., Droguett A., Burgos M.E., Ardiles L., Flores C., et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 2004, 19:2505-2512.
145. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58:1492-1499.
146. Tashiro K., Koyanagi I., Saitoh A., Shimizu A., Shike T., Ishiguro C., et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2002, 16:1-4.
147. Wang Q.Y., Chen F.Q. Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus. Diabetes Res Clin Pract 2009, 83:215-219.
148. Park J., Ryu D.R., Li J.J., Jung D.S., Kwak S.J., Lee S.H., et al. MCP-1/CCR2 system is involved in high glucose-induced fibronectin and type IV collagen expression in cultured mesangial cells. Am J Physiol Renal Physiol 2008, 295:F749-F757.
149. Ihm C.G., Park J.K., Hong S.P., Lee T.W., Cho B.S., Kim M.J., et al. A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 1998, 79:33-37.
150. Ibrahim S., Rashed L. Correlation of urinary monocyte chemo-attractant protein-1 with other parameters of renal injury in type-II diabetes mellitus. Saudi J Kidney Dis Transpl 2008, 19:911-917.
151. von Schacky C., Baumann K., Angerer P. The effect of n-3 fatty acids on coronary atherosclerosis: results from SCIMO, an angiographic study, background and implications. Lipids 2001, 36:S99-S102.
152. Banba N., Nakamura T., Matsumura M., Kuroda H., Hattori Y., Kasai K. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 2000, 58:684-690.
153. Matsui T., Yamagishi S., Ueda S., Nakamura K., Imaizumi T., Takeuchi M., et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007, 35:482-489.
154. Wang S.N., LaPage J., Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int 2000, 57:1002-1014.
155. Wang S.N., LaPage J., Hirschberg R. Pathophysiologic glomerulotubular growth factor link. Miner Electrolyte Metab 1999, 25:234-241.
156. Morii T., Fujita H., Narita T., Koshimura J., Shimotomai T., Fujishima H., et al. Increased urinary excretion of monocyte chemoattractant protein-1 in proteinuric renal diseases. Ren Fail 2003, 25:439-444.
157. Zheng M., Ye S., Zhai Z., Chen Y., Li X., Yang G., et al. Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression. J Diabetes Complicat 2009, 23:124-129.
158. Bao Y., Jia R.H., Yuan J., Li J. Rosiglitazone ameliorates diabetic nephropathy by inhibiting reactive oxygen species and its downstream-signaling pathways. Pharmacology 2007, 80:57-64.
159. Gruden G., Setti G., Hayward A., Sugden D., Duggan S., Burt D., et al. Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 2005, 16:688-696.
160. Ohta M.Y., Nagai Y., Takamura T., Nohara E., Kobayashi K. Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells. Metabolism 2000, 49:163-166.
161. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Song H.K., Han K.H., et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008, 23:2750-2760.
162. Fujita H., Koshimura J., Sato T., Miura T., Sasaki H., Morii T., et al. Effects of long-term pravastatin treatment on serum and urinary monocyte chemoattractant protein-1 levels and renal function in type 2 diabetic patients with normoalbuminuria. Ren Fail 2007, 29:791-796.
163. Ota T., Takamura T., Ando H., Nohara E., Yamashita H., Kobayashi K. Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 2003, 46:843-851.
164. Mizuno M., Sada T., Kato M., Fukushima Y., Terashima H., Koike H. The effect of angiotensin II receptor blockade on an end-stage renal failure model of type 2 diabetes. J Cardiovasc Pharmacol 2006, 48:135-142.
165. Lee F.T., Cao Z., Long D.M., Panagiotopoulos S., Jerums G., Cooper M.E., et al. Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. J Am Soc Nephrol 2004, 15:2139-2151.
166. Kato S., Luyckx V.A., Ots M., Lee K.W., Ziai F., Troy J.L., et al. Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats. Kidney Int 1999, 56:1037-1048.
167. Wu Y.G., Lin H., Qian H., Zhao M., Qi X.M., Wu G.Z., et al. Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm Res 2006, 55:192-199.
168. Amann B., Tinzmann R., Angelkort B. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 2003, 26:2421-2425.
169. Han S.Y., Kim C.H., Kim H.S., Jee Y.H., Song H.K., Lee M.H., et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006, 17:1362-1372.
170. Takebayashi K., Matsumoto S., Aso Y., Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006, 91:2214-2217.
171. Cha D.R., Kang Y.S., Han S.Y., Jee Y.H., Han K.H., Kim H.K., et al. Role of aldosterone in diabetic nephropathy. Nephrology (Carlton) 2005, 10:S37-S39.
172. Zhang Y., Chen B., Hou X.H., Guan G.J., Liu G., Liu H.Y., et al. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats. Chin Med J (Engl) 2007, 120:988-995.
173. Wu Y.G., Lin H., Qi X.M., Wu G.Z., Qian H., Zhao M., et al. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes. Int Immunopharmacol 2006, 6:445-453.
174. Kikuchi Y., Imakiire T., Yamada M., Saigusa T., Hyodo T., Hyodo N., et al. Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats. Nephrol Dial Transplant 2005, 20:1573-1581.
175. Wu Y., Wu G., Qi X., Lin H., Qian H., Shen J., et al. Protein kinase C beta inhibitor LY333531 attenuates intercellular adhesion molecule-1 and monocyte chemotactic protein-1 expression in the kidney in diabetic rats. J Pharmacol Sci 2006, 101:335-343.
176. Wang F., Li M., Cheng L., Zhang T., Hu J., Cao M., et al. Intervention with cilostazol attenuates renal inflammation in streptozotocin-induced diabetic rats. Life Sci 2008, 83:828-835.
177. Takebayashi K., Suetsugu M., Matsumoto S., Aso Y., Inukai T. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J 2009, 102:361-368.
178. Kanamori H., Matsubara T., Mima A., Sumi E., Nagai K., Takahashi T., et al. Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochem Biophys Res Commun 2007, 360:772-777.
179. Song H.X., Gong J., Chen W. Effect of triptolide on urinary monocyte chemottractant protein-1 in patients with diabetic nephropathy. Zhongguo Zhong Xi Yi Jie He Za Zhi 2005, 25:416-418.
180. Kang E.S., Lee G.T., Kim B.S., Kim C.H., Seo G.H., Han S.J., et al. Lithospermic acid B ameliorates the development of diabetic nephropathy in OLETF rats. Eur J Pharmacol 2008, 579:418-425.
181. Qi X.M., Wu G.Z., Wu Y.G., Lin H., Shen J.J., Lin S.Y. Renoprotective effect of breviscapine through suppression of renal macrophage recruitment in streptozotocin-induced diabetic rats. Nephron Exp Nephrol 2006, 104:147-157.
182. Sato S., Yamate J., Hori Y., Hatai A., Nozawa M., Sagai M. Protective effect of polyphenol-containing azuki bean (Vigna angularis) seed coats on the renal cortex in streptozotocin-induced diabetic rats. J Nutr Biochem 2005, 16:547-553.
183. Li J.J., Lee S.H., Kim D.K., Jin R., Jung D.S., Kwak S.J., et al. Colchicine attenuates inflammatory cell infiltration and extracellular matrix accumulation in diabetic nephropathy. Am J Physiol Renal Physiol 2009, 297:F200-F209.
184. Han S.Y., So G.A., Jee Y.H., Han K.H., Kang Y.S., Kim H.K., et al. Effect of retinoic acid in experimental diabetic nephropathy. Immunol Cell Biol 2004, 82:568-576.
185. Zhang Z., Yuan W., Sun L., Szeto F.L., Wong K.E., Li X., et al. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007, 72:193-201.
186. Chiarelli F., Cipollone F., Mohn A., Marini M., Iezzi A., Fazia M., et al. Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes. Diabetes Care 2002, 25:1829-1834.
187. Manabe E., Handa O., Naito Y., Mizushima K., Akagiri S., Adachi S., et al. Astaxanthin protects mesangial cells from hyperglycemia-induced oxidative signaling. J Cell Biochem 2008, 103:1925-1937.
188. Hagiwara S., Makita Y., Gu L., Tanimoto M., Zhang M., Nakamura S., et al. Eicosapentaenoic acid ameliorates diabetic nephropathy of type 2 diabetic KKAy/Ta mice. involvement of MCP-1 suppression and decreased ERK1/2 and p38 phosphorylation. Nephrol Dial Transplant 2006, 21:605-615.
189. Garman J.H., Mulroney S., Manigrasso M., Flynn E., Maric C. Omega-3 fatty acid rich diet prevents diabetic renal disease. Am J Physiol Renal Physiol 2009, 296:F306-F316.
190. Aoyama I., Shimokata K., Niwa T. An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron 2002, 92:635-651.
191. Zhang C., Tan Y., Guo W., Li C., Ji S., Li X., et al. Attenuation of diabetes-induced renal dysfunction by multiple exposures to low-dose radiation is associated with the suppression of systemic and renal inflammation. Am J Physiol Endocrinol Metab 2009, 297:E1366-E1377.
192. Zhang W., Liu H., Al-Shabrawey M., Caldwell R.W., Caldwell R.B. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res 2011, 2:96-103.
193. Abu El-Asrar A.M., Struyf S., Kangave D., Geboes K., Van Damme J. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 2006, 17:155-165.
194. Harada C., Okumura A., Namekata K., Nakamura K., Mitamura Y., Ohguro H., et al. Role of monocyte chemotactic protein-1 and nuclear factor kappa B in the pathogenesis of proliferative diabetic retinopathy. Diabetes Res Clin Pract 2006, 74:249-256.
195. Capeans C., De Rojas M.V., Lojo S., Salorio M.S. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998, 18:546-550.
196. Mitamura Y., Takeuchi S., Matsuda A., Tagawa Y., Mizue Y., Nishihira J. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 2001, 215:415-418.
197. Hernández C., Segura R.M., Fonollosa A., Carrasco E., Francisco G., Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005, 22:719-722.
198. Tashimo A., Mitamura Y., Nagai S., Nakamura Y., Ohtsuka K., Mizue Y., et al. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. Diabet Med 2004, 21:1292-1297.
199. Abu el-Asrar A.M., Van Damme J., Put W., Veckeneer M., Dralands L., Billiau A., et al. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997, 123:599-606.
200. Matsumoto Y., Takahashi M., Ogata M. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Nippon Ganka Gakkai Zasshi 2001, 105:435-441.
201. Murugeswari P., Shukla D., Rajendran A., Kim R., Namperumalsamy P., Muthukkaruppan V. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina 2008, 28:817-824.
202. Maier R., Weger M., Haller-Schober E.M., El-Shabrawi Y., Wedrich A., Theisl A., et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis 2008, 14:637-643.
203. Elner S.G., Elner V.M., Jaffe G.J., Stuart A., Kunkel S.L., Strieter R.M. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995, 14:1045-1053.
204. Ozturk B.T., Bozkurt B., Kerimoglu H., Okka M., Kamis U., Gunduz K. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis 2009.
205. Böni-Schnetzler M., Ehses J.A., Faulenbach M., Donath M.Y. Insulitis in type 2 diabetes. Diabetes Obes Metab 2008, 10(Suppl. 4):201-204.
206. Reddy S., Bai Y., Robinson E., Ross J. Immunolocalization of monocyte chemoattractant protein-1 in islets of NOD mice during cyclophosphamide administration. Ann NY Acad Sci 2006, 1079:103-108.
207. Cabric S., Sanchez J., Lundgren T., Foss A., Felldin M., Källen R., et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007, 56:2008-2015.
208. Schröppel B., Zhang N., Chen P., Chen D., Bromberg J.S., Murphy B. Role of donor-derived monocyte chemoattractant protein-1 in murine islet transplantation. J Am Soc Nephrol 2005, 16:444-451.
209. Toyama H., Takada M., Suzuki Y., Kuroda Y. Activation of macrophage-associated molecules after brain death in islets. Cell Transplant 2003, 12:27-32.
210. Ehrnfelt C., Kumagai-Braesch M., Uzunel M., Holgersson J. Adult porcine islets produce MCP-1 and recruit human monocytes in vitro. Xenotransplantation 2004, 11:184-194.
211. Lloyd C.M., Minto A.W., Dorf M.E., Proudfoot A., Wells T.N., Salant D.J., et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997, 185:1371-1380.
212. Haringman J.J., Gerlag D.M., Smeets T.J., Baeten D., van den Bosch F., Bresnihan B., et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthr Rheum 2006, 54:2387-2392.
213. Horvath C., Welt F.G., Nedelman M., Rao P., Rogers C. Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ Res 2002, 90:488-494.
214. Brühl H., Cihak J., Schneider M.A., Plachý J., Rupp T., Wenzel I., et al. Dual role of CCR2 during initiation and progression of collagen-induced arthritis: evidence for regulatory activity of CCR2+ T cells. J Immunol 2004, 172:890-898.
215. Brodmerkel C.M., Huber R., Covington M., Diamond S., Hall L., Collins R., et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol 2005, 175:5370-5378.
216. Gong J.H., Clark-Lewis I. Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2-terminal residues. J Exp Med 1995, 181:631-640.
217. Gong J.H., Ratkay L.G., Waterfield J.D., Clark-Lewis I. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. J Exp Med 1997, 186:131-137.
218. Nakano K., Egashira K., Ohtani K., Zhao G., Funakoshi K., Ihara Y., et al. Catheter-based adenovirus-mediated anti-monocyte chemoattractant gene therapy attenuates in-stent neointima formation in cynomolgus monkeys. Atherosclerosis 2007, 194:309-316.
219. Schepers A., Eefting D., Bonta P.I., Grimbergen J.M., de Vries M.R., van Weel V., et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 2006, 26:2063-2069.
220. Proudfoot A.E., Handel T.M., Johnson Z., Lau E.K., LiWang P., Clark-Lewis I., et al. Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines. Proc Natl Acad Sci USA 2003, 100:1885-1890.
221. Handel T.M., Johnson Z., Rodrigues D.H., Dos Santos A.C., Cirillo R., Muzio V., et al. An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo. J Leukoc Biol 2008, 84:1101-1108.
222. Rot A. Neutrophil attractant/activation protein-1 (interleukin-8) induces in vitro neutrophil migration by haptotactic mechanism. Eur J Immunol 1993, 23:303-306.
223. Lau E.K., Paavola C.D., Johnson Z., Gaudry J.P., Geretti E., Borlat F., et al. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. J Biol Chem 2004, 279:22294-22305.
224. Liehn E.A., Piccinini A.M., Koenen R.R., Soehnlein O., Adage T., Fatu R., et al. A new monocyte chemotactic protein-1/chemokine CC motif ligand-2 competitor limiting neointima formation and myocardial ischemia/reperfusion injury in mice. J Am Coll Cardiol 2010, 56:1847-1857.
225. Piccinini A.M., Knebl K., Rek A., Wildner G., Diedrichs-Möhring M., Kungl A.J. Rationally evolving MCP-1/CCL2 into a decoy protein with potent anti-inflammatory activity in vivo. J Biol Chem 2010, 285:8782-8792.